Acute Lymphoblastic Leukemia (ALL) Clinical Trials

Find Acute Lymphoblastic Leukemia (ALL) Clinical Trials Near You

Assessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma

Status: Recruiting
Location: See location...
Intervention Type: Other, Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Objectives: * To determine the sensitivity and specificity of heart rate variability (HRV), measured remotely with biosensor technology (Actigraph LEAP), compared to in-person assessment using the Ewing battery as the reference standard to identify cardiac autonomic dysfunction (AD) among survivors of leukemia and lymphoma. * To determine the sensitivity and specificity of the Composite Autonomic Symptom Scale 31 (COMPASS31) compared to the Ewing battery to identify AD among leukemia and lymphoma survivors.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Participants enrolled in St. Jude Lifetime Cohort (SJLIFE) \>18 years of age.

• Primary diagnosis of acute lymphoblastic leukemia (ALL), Hodgkin's Lymphoma (HL), or Non-Hodgkin's Lymphoma (Non-HL).

• Not currently taking beta-blocker medication.

Locations
United States
Tennessee
St. Jude Children's Research Hospital
RECRUITING
Memphis
Contact Information
Primary
Kirsten K Ness, PhD
referralinfo@stjude.org
866-278-5833
Time Frame
Start Date: 2025-02-03
Estimated Completion Date: 2026-06
Participants
Target number of participants: 188
Treatments
Experimental: Screening (COMPASS31 + battery assessment + heart monitor)
Patients complete the COMPASS31 questionnaire and undergo an in-person Ewing battery assessment over 60-90 minutes on study. Patients then wear a biosensensor heart monitor for 7 days to monitor heart rate variability remotely on study.
Experimental: Screening (battery assessment + COMPASS31 + heart monitor)
Patients undergo an in-person Ewing battery assessment over 60-90 minutes and complete the COMPASS31 questionnaire on study. Patients then wear a biosensensor heart monitor for 7 days to monitor heart rate variability remotely on study.
Related Therapeutic Areas
Acute Lymphoblastic Leukemia (ALL)
Leukemia
Sponsors
Leads: St. Jude Children's Research Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors

LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors

Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Biological
Study Phase: Phase 1/Phase 2

Phase I Study of Activated T-Cells Expressing Second or Third Generation CD19-Specific Chimeric Antigen Receptors for Advanced B-Cell Non-Hodgkin's Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia (SAGAN)

Phase I Study of Activated T-Cells Expressing Second or Third Generation CD19-Specific Chimeric Antigen Receptors for Advanced B-Cell Non-Hodgkin's Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia (SAGAN)

Who is this study for: Patients with Chronic Lymphocytic Leukemia or Acute Lymphoblastic Leukemia
Enrollment Status: Recruiting
Publish Date: January 05, 2026
Intervention Type: Genetic
Study Drugs: Fludarabine, Cyclophosphamide, CD19 CAR-T Cells
Study Phase: Phase 1

INITIALL: Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

INITIALL: Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Enrollment Status: Recruiting
Publish Date: March 03, 2026
Intervention Type: Drug
Study Phase: Phase 4
View All